Department of Preventive Veterinary Medicine, Veterinary School, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Department of Preventive Veterinary Medicine, Veterinary School, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Fish Shellfish Immunol. 2022 Aug;127:405-411. doi: 10.1016/j.fsi.2022.06.040. Epub 2022 Jun 27.
Francisella orientalis infections, known as francisellosis, are one of the most important diseases affecting the production of Nile tilapia, causing high mortality rates in the most susceptible fish stages: fingerlings and juveniles. Antibiotic therapy is the method of choice for treating the disease, as there are no commercially available vaccines. In this study, we developed an inactivated whole-cell vaccine using an isolate of F. orientalis in combination with the aqueous adjuvant Montanide IMS 1312 VG, which was administered to Nile tilapia through immersion. Two immunization trials (1 and 2) were conducted with fish at the fingerling and juvenile stages. For each trial, five different experimental groups were established: a complete vaccine (bacterin in combination with aqueous adjuvant), bacterin, aqueous adjuvant, and positive and negative controls. Thirty days after vaccination, an experimental challenge was performed through intraperitoneal injection of the same F. orientalis isolate. As a result, the vaccinated fingerlings were the only group in which mortality and progression of clinical signs of francisellosis were statistically significantly reduced, although relative percentage of survival (RPS) was low at 50%. In the juvenile group, RPS was higher at 63%, but not statistically significant. Nevertheless, an RPS of only 50% is acceptable for using vaccines in the field. The bacterin and adjuvant treatments alone were not effective, showing an RPS of 37% and 0%, respectively. Post-vaccination mortality was observed in the group exposed only to the adjuvant, which may indicate excessive immune stimulation at this stage. Interestingly, the immune response elicited by the vaccine was unable to eliminate the pathogen from the host; therefore, the surviving animals became carriers. Although the immune response elicited by the vaccine was unable to eliminate the pathogen from the host, this vaccine formulation could be a viable alternative for use in the field and serve as another means of controlling the mortality caused by the pathogen. Our study provides the first report of vaccination, using immersion, against francisellosis at the most susceptible stages of farmed Nile tilapia. Future studies should address the efficiency of immersion vaccines under field conditions.
东方弗朗西斯菌感染,又称弗朗西斯菌病,是影响尼罗罗非鱼生产的最重要疾病之一,在最易感的鱼类阶段:鱼苗和幼鱼中导致高死亡率。抗生素治疗是治疗这种疾病的首选方法,因为没有商业上可用的疫苗。在这项研究中,我们使用东方弗朗西斯菌分离株和水性佐剂 Montanide IMS 1312 VG 开发了一种灭活全细胞疫苗,通过浸泡将其施用于尼罗罗非鱼。在鱼苗和幼鱼阶段进行了两次免疫试验(1 和 2)。对于每个试验,建立了五个不同的实验组:完整疫苗(细菌与水性佐剂的组合)、细菌、水性佐剂、阳性和阴性对照。接种后 30 天,通过腹腔内注射相同的东方弗朗西斯菌分离株进行实验性挑战。结果,接种的鱼苗是唯一一组死亡率和弗朗西斯菌病临床症状进展在统计学上显著降低的组,尽管相对存活率(RPS)较低为 50%。在幼鱼组中,RPS 为 63%,但没有统计学意义。尽管如此,现场使用疫苗的 RPS 仅为 50%是可以接受的。单独使用细菌和佐剂处理均无效,RPS 分别为 37%和 0%。仅暴露于佐剂的组在接种后观察到死亡率,这可能表明在此阶段过度的免疫刺激。有趣的是,疫苗引起的免疫反应未能从宿主中消除病原体;因此,幸存的动物成为携带者。尽管疫苗引起的免疫反应未能从宿主中消除病原体,但这种疫苗配方可能是现场使用的可行替代方案,并作为控制病原体引起的死亡率的另一种手段。我们的研究首次报道了在养殖尼罗罗非鱼最易感阶段通过浸泡接种弗朗西斯菌病。未来的研究应解决现场条件下浸泡疫苗的效率问题。